ArticleScience advances2018
An enzymatic approach reverses nicotine dependence, decreases compulsive-like intake, and prevents relapse.
Article in Science advances, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 30 citations in OpenAlex.
- The microbiome regulates host metabolic health and diseases through microbial enzymes.Nature reviews. Gastroenterology & hepatology · 2026Review
- Oxytocin treatment rescues irritability-like behavior in Cc2d1a conditional knockout mice.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024Article
- Acute nicotine activates orectic and inhibits anorectic brain regions in rats exposed to chronic nicotine.Neuropharmacology · 2024Article
- Rational Design of a Flavoenzyme for Aerobic Nicotine Catabolism.bioRxiv : the preprint server for biology · 2024Article
- Vaccines to Treat Substance Use Disorders: Current Status and Future Directions.Pharmaceutics · 2024Review
- Directed evolution unlocks oxygen reactivity for a nicotine-degrading flavoenzyme.Nature chemical biology · 2023Article
- New medications development for smoking cessation.Addiction neuroscience · 2023Article
- The effect of CNQX on self-administration: present in nicotine, absent in methamphetamine model.Frontiers in behavioral neuroscience · 2023Article
- Immunotherapies for the Treatment of Drug Addiction.Vaccines · 2022Review
- Binding Interface and Electron Transfer Between Nicotine Oxidoreductase and Its Cytochrome c Electron Acceptor.Biochemistry · 2022Article
- Animal Models of the Behavioral Symptoms of Substance Use Disorders.Cold Spring Harbor perspectives in medicine · 2021Review
- A cytochrome c is the natural electron acceptor for nicotine oxidoreductase.Nature chemical biology · 2021Article
- Advances in smoking cessation pharmacotherapy: Non-nicotinic approaches in animal models.Neuropharmacology · 2020Review
- Article
- Oxycodone self-administration and withdrawal behaviors in male and female Wistar rats.Psychopharmacology · 2020Article
- Chronic voluntary caffeine intake in male Wistar rats reveals individual differences in addiction-like behavior.Pharmacology, biochemistry, and behavior · 2020Article
- Nicotinic Receptors Underlying Nicotine Dependence: Evidence from Transgenic Mouse Models.Current topics in behavioral neurosciences · 2020Article
- Optimization of a nicotine degrading enzyme for potential use in treatment of nicotine addiction.BMC biotechnology · 2019Article
- Dopamine DFrontiers in behavioral neuroscience · 2019Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Tobacco use disorder is the leading cause of disease and preventable death worldwide, but current medications that are based on pharmacodynamics have low efficacy. Novel pharmacokinetic approaches to prevent nicotine from reaching the brain have been tested using vaccines, but these efforts have failed because antibody affinity and concentration are not sufficient to completely prevent nicotine from reaching the brain. We provide preclinical evidence of the efficacy of an enzymatic approach to reverse nicotine dependence, reduce compulsive-like nicotine intake, and prevent relapse in rats with a history of nicotine dependence. Chronic administration of NicA2-J1, an engineered nicotine-degrading enzyme that was originally isolated from
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.